NorthWest Biotherapeutics Inc (NWBO)

[survivor1x]

With respect to the median.

She was talking in general about the limitations of clinical trials up to date in cancer. What the Oncology field as a whole now understands that just because you have melanoma it may not be the same as another patients melanoma yet clinical trials to date measure the groups of patients as a whole that may give signals of reduced efficacy because of non responders (If it only works in 30% of patients it's past the median). She also states that some companies may be unwilling to only work on just these subgroups because they then can only sell a drug to these subgroups. So it can pose a challenge. Note she was not speaking about DC VAX, just cancer treatments in general. DC VAX was a follow up question and she said it's out of her control as far as un-blinding, she didn't want to comment any further because the trial was still ongoing but was looking forward to unblinding so she can learn from both repsonders and non-responders.

As far a combo treatments she was saying that cancer finds a way to come back or adapt to 1 treatment so to hit a cancer after its been weekend by 1 treatment with another.

I did not hear anything in this interview that would give me pause with respect to the DC VAX trial. Most of this was high level general information.